Affection of cardiovascular system in diabetic patients with thyroid dysfunctions
Authors:
Z. Schroner 1; I. Lazúrová 2
Authors‘ workplace:
NZZ interná a diabetologická ambulancia, Moldava nad Bodvou, Slovenská republika
1; I. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura, Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc.
2
Published in:
Vnitř Lék 2006; 52(11): 1069-1076
Category:
Review
Overview
Affection of cardiovascular system is one of the most frequent and – especially in higher age groups – the most serious clinical manifestations of thyroid dysfunction. Moreover, diabetics, mainly type 2 diabetes patients, have a marked predisposition to cardiovascular diseases, especially to atherosclerosis and its visceral complications. Simultaneous occurrence of diabetes mellitus (DM) and thyroid dysfunctions involves a very high risk of development and progression of various forms of cardiovascular diseases. There are two basal aspects of the influence of hypothyreosis on cardiovascular system. Decreasing basal metabolism in the whole organism reduces requirements on the cardiovsuclar system. The second aspect of the influence of hypothyreosis on the cardiovascular system is its atherogenic effect. Hypothyreosis in diabetics accelerates the development of chronic, primarily macroangiopathic complications. As opposed to hypothyreosis, the clinical picture of which is not characterised by cardiovascular system disorders, cardiac involvement in patients with hyperthyreosis is more pronounced. In older diabetics hyperthyreosis is often manifested only by cardiovascular symptomatology. Subclinical hyperthyreosis in DM patients may stimulate cardiac function and increase the risk of atrial fibrillation.
Key words:
cardiovascular system – diabetes mellitus – hypothyreosis – hyperthyreosis
Sources
1. Zamrazil V, Váňa S, Němec J. Štítná žláza a kardiovaskulárny systém. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 468–477.
2. Belicová M, Smatanová S, Lilgová M et al. Diabetes mellitus a srdce. Diabetes a obezita 2003; 3: 8–16.
3. Klein I, Ojama K Cardiovascular manifestations of endocrine diseases. J Clin Endocrin Metab 1992; 75: 339–342.
4. Běhanová M, Nedvídková J. Periférní účinky tyreoidálních hormonu. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 283–295.
5. Payer J. Kardiálne prejavy hypertyreózy. Kardiológia 1997; 6: 71–74.
6. Polikar R, Burger AG, Scherrer U et al. The thyroid and the heart. Circulation 1993; 87: 1435–1441.
7. Klein J, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotypically transplanted rat heart. J Clin Invest 1986; 77: 1694–1698.
8. Kahaly G, Beyer J. Kardiale beteiligung bei Functionsstorungen der Schilddruse. Dtsch Med Wschr 1991; 116: 1559–1562.
9. Klein I, Levy GS. New perspectives on thyroid hormone, catecholamines and heart. Am J Med 1984; 76: 167–172.
10. Forfar J, Caldwell G. Hyperthyroid heart disease. J Clin Endocrin Metab 1985; 14: 491–508.
11. De Groot WJ, Leonard J. Hyperthyreoidism as a high cardiac output state. Am Heart J 1970; 79: 265–275.
12. Král J, Hradec J et al. Heart in thyroid diseases. Cor Vasa 1992; 34: 108–114.
13. Woeber KA Thyrotoxicosis and the heart. N Engl J Med 1992; 327: 94–98.
14. Vondra K, Zamrazil V. Onemocnění štítné žlázy u nemocných s diabetes mellitus. DMEV 2002; 5: 78–84.
15. Schroner Z, Pella J. Diabetes mellitus v skratke. Košice: Oriens 2002.
16. Rašlová K, Flipová G, Mikeš Z et al. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých. Lipidový konsenzus – 2. Interná med 2002; 3: 10–18.
17. Tkáč I Možnosti prevencie aterosklerózy pri diabetes mellitus 2. typu. Interná Med 2003; 3: 149–153.
18. Krahulec B. Inzulínová rezistencia a kardiovaskulárne následky – významaná úloha endotelovej dysfunkcie. Diabetes a obezita 2003; 3: 9–15.
19. Hak AE, Pols HAP et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Int Med 2000; 132: 270–278.
20. Bakker SJL, Maaten JC, Popp-Snijders C et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001; 86: 1206–1211.
21. Lien EA, Nedrebo BG, Varhaug JE et al. Plasma total homocystein levels during short term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000; 85: 1049–1053.
22. Pella D, Rybár R et al. Ateroskleróza a artériová hypertenzia. Interná med 2001; 1: 86–90.
23. Češka R. Cholesterol a ateroskleróza. Praha: Maxdorf, 1990.
24. Vrablík M, Češka R. Sekundární dyslipoproteinémie. Via Practica 2004; 1: 14–17.
25. Fabryová Ľ. Manažment kardiovaskulárneho rizika u pacientov s metabolickým syndrómom. Interná Med 2004; 4: 35–42.
26. Fabryová Ľ. Dyslipoproteinémie. In: Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Bratislava: Academic Electronic Press 2004: 553–567.
27. Límanová Z. Choroby štítné žlázy. In: Klener P et al. Vnitřní lékařství. Praha: Galén 2001: 763–777.
28. Kiňová S. Endokrinné formy hypertenzie. Interná Med 2004; 4: 286–290.
29. Vavrejnová V, Nedvídková J et al. Zvýšení hladiny noradrenalinu při hypotyreoze a jeho souvislosti s činností kardiovaskulárního systému. Vnitř Lék 1992; 38: 1195–1200.
30. Phull PS, Collins CE et al. Variant angina in thyrotoxicosis. Br J Clin P 1993; 47: 17–19.
31. Němec J, Stárka L Preklinické poruchy tyreoidální funkce. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 392–399.
32. Límanová Z, Němec J, Zamrazil V. Nemoci štítné žlázy. Praha: Galén 1997.
33. Presti CHF, Hart R Thyrotoxicosis, atrial fibrillation and embolism revisited. Am Heart J 1989; 4: 975–976.
34. Nakazawa HK, Sakuri K et al. Management of atrial fibrillation in the post thyrotoxic state. Am J Med 1982; 72: 903–906.
35. Zamrazil V, Němec J. Vliv amiodaronu na štítnou žlázu. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 415–424.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2006 Issue 11
Most read in this issue
- Male hormonal contraception
- Transfusion-induced immunomodulation and infectious complications
- Mitral regurgitation: are we able to properly time the surgical procedure?
- Massive pulmonary embolism – attempt at embolectomy following the failure of thrombolytic treatment